WallStSmart

Cosmos Health Inc. (COSM)vsMcKesson Corporation (MCK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

McKesson Corporation generates 609592% more annual revenue ($397.96B vs $65.27M). MCK leads profitability with a 1.1% profit margin vs -29.3%. MCK earns a higher WallStSmart Score of 62/100 (C+).

COSM

Hold

38

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 4/9Altman Z: -2.25

MCK

Buy

62

out of 100

Grade: C+

Growth: 8.0Profit: 4.5Value: 8.0Quality: 6.3
Piotroski: 6/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

MCKUndervalued (+63.8%)

Margin of Safety

+63.8%

Fair Value

$2633.99

Current Price

$725.17

$1908.82 discount

UndervaluedFair: $2633.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM2 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
38.5%10/10

Revenue surging 38.5% year-over-year

MCK5 strengths · Avg: 8.6/10
Debt/EquityHealth
-6.6410/10

Conservative balance sheet, low leverage

Market CapQuality
$92.45B9/10

Large-cap with strong market position

PEG RatioValuation
0.908/10

Growing faster than its price suggests

EPS GrowthGrowth
38.0%8/10

Earnings expanding 38.0% YoY

Free Cash FlowQuality
$3.42B8/10

Generating 3.4B in free cash flow

Areas to Watch

COSM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$17.39M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-89.1%2/10

ROE of -89.1% — below average capital efficiency

Free Cash FlowQuality
$-4.70M2/10

Negative free cash flow — burning cash

MCK3 concerns · Avg: 3.0/10
Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
1.1%3/10

1.1% margin — thin

Operating MarginProfitability
1.6%3/10

Operating margin of 1.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Price/Book, Revenue Growth. Revenue growth of 38.5% demonstrates continued momentum.

Bull Case : MCK

The strongest argument for MCK centers on Debt/Equity, Market Cap, PEG Ratio. Revenue growth of 11.4% demonstrates continued momentum. PEG of 0.90 suggests the stock is reasonably priced for its growth.

Bear Case : COSM

The primary concerns for COSM are EPS Growth, Market Cap, Return on Equity.

Bear Case : MCK

The primary concerns for MCK are Return on Equity, Profit Margin, Operating Margin. Thin 1.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

COSM profiles as a hypergrowth stock while MCK is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.30 — expect wider price swings.

COSM is growing revenue faster at 38.5% — sustainability is the question.

MCK generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

MCK scores higher overall (62/100 vs 38/100) and 11.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

McKesson Corporation

HEALTHCARE · MEDICAL DISTRIBUTION · USA

McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.

Visit Website →

Want to dig deeper into these stocks?